OncoMatch/Clinical Trials/NCT07047586
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Is NCT07047586 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Lenvatinib for hepatocellular carcinoma (hcc).
Treatment: Tislelizumab · Lenvatinib — To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy — combination with bevacizumab
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC
Must have received: anti-PD-L1 therapy — combination with bevacizumab
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC
Must have received: VEGF inhibitor (bevacizumab) — combination with anti-PD-1/PD-L1
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC
Lab requirements
Blood counts
absolute neutrophil count ≥ 1,500/L, platelets ≥60 x10^3/L
Kidney function
Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula)
Liver function
Child-Pugh scores 5-7; Total bilirubin ≤ 3x upper normal limit; AST/ALT ≤ 5x ULN; INR ≤1.25; Albumin ≥ 31 g/dL
Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1,500/L, platelets ≥60 x103/L; Total bilirubin ≤ 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31 g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07047586 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anti-PD-1 therapy and anti-PD-L1 therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages